EU's CHMP Clears Selincro And Perjeta, Rejects Kynamro And Fanaptum
This article was originally published in The Pink Sheet Daily
Executive Summary
Europe's top scientific advisory panel backed Lundbeck's alcoholism therapy Selincro (nalmefene) and Roche's next-generation breast cancer therapy Perjeta (pertuzumab) but rejected Genzyme/Isis' antisense therapy Kynamro (mipomersen) and Vanda's Fanaptum (oral iloperidone).